Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.55 and traded as high as $0.57. Xtant Medical shares last traded at $0.55, with a volume of 14,574 shares trading hands.
Xtant Medical Trading Down 1.3%
The firm has a fifty day moving average of $0.64 and a 200 day moving average of $0.55. The firm has a market capitalization of $76.97 million, a PE ratio of -6.14 and a beta of -0.21. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.03 and a current ratio of 2.34.
Institutional Trading of Xtant Medical
A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC boosted its holdings in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 798,033 shares of the medical device company's stock after purchasing an additional 103,825 shares during the period. Renaissance Technologies LLC owned about 0.57% of Xtant Medical worth $354,000 at the end of the most recent reporting period. Institutional investors own 69.33% of the company's stock.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
